Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Atherosclerosis)
Source: Atherosclerosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Statin-induced immune-mediated necrotizing myopathy with concomitant increase of anti-HMGCR and anti-ACHR antibodies
We present a case of a patient with a severe phenotype of the disease that was found to have an increase in anti-HMGCR and anti-ACHR antibodies. A potential association between these antibodies have not been previously described. A 67-year-old male with hyperlipidemia, who was recently initiated on atorvastatin therapy, presented to the ED with progressive muscle weakness. Within a few days of admission, the patient developed complete flaccid paralysis and respiratory distress requiring intubation. The patient ’s CK was elevated to 24,000 and there was an increase of anti-HMGCR and anti-ACHR antibodies. Impressions from ...
Source: Rheumatology International - April 2, 2024 Category: Rheumatology Source Type: research
Effect of Statin Treatment in Patients with Aneurysmal Subarachnoid Hemorrhage: A Network Meta-Analysis
ConclusionsSimvastatin 80 mg might be the most effective intervention in reducing DCI. Additionally, short-term therapy might provide more benefits. Further research with longer follow-up is warranted to validate the current findings in patients with aSAH who are at high risk of DCI. (Source: Neurocritical Care)
Source: Neurocritical Care - April 2, 2024 Category: Neurology Source Type: research
